ProfileGDS5678 / 1423779_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 88% 87% 87% 85% 86% 89% 89% 88% 87% 87% 87% 87% 87% 87% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.7744488
GSM967853U87-EV human glioblastoma xenograft - Control 26.6565387
GSM967854U87-EV human glioblastoma xenograft - Control 36.7266387
GSM967855U87-EV human glioblastoma xenograft - Control 46.5486285
GSM967856U87-EV human glioblastoma xenograft - Control 56.54586
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.8757489
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.869289
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.813388
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.7254187
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.7957587
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.7291987
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.7048387
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.7294387
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.7321487